<aside> 📺

Watch this 4 min video to learn how starting from your own technology description can find and evaluate in a few minutes the right Strategic Partners and possible Acquirers by using scientific and business signals. This is useful as Startup Founder/BD or when evaluating investment/M&A/licensing/partnering candidates as a pharma company or investor.

https://share.descript.com/view/EloXXY6dWux

</aside>

<aside> 1️⃣

Start from your/a startup’s technology:

Example: Go to NurExone Biologic profile and Ask Anything:

<aside> ❓

I want to find the most likely acquirers for this company. For what indications may this technology be really valuable? Who are likely candidates? Give me a search query (with these operators: AND OR () "") with such diseases I can use to find companies.

</aside>

• AI Answer: (click to open) </aside>

<aside> 2️⃣

In a new tab: Query in Companies:

<aside> 🔎

("spinal cord injury" OR "central nervous system injury" OR "traumatic brain injury" OR "stroke" OR "neuroregeneration" OR "optic nerve injury" OR "vision restoration" OR "multiple sclerosis" OR "ALS" OR "neurodegeneration")

</aside>

</aside>

<aside> 3️⃣

Filter companies:

<aside> ✅

Large Pharma

</aside>

</aside>

<aside> 3️⃣

Visit a profile, example Biogen - AI Evaluation - Collaboration Potential

Collaboration Context:

<aside> ❓

We are a biotech startup identifying potential acquirers mid- to long term

</aside>

Criteria:

<aside> ❓

Find below context on who our exosome technology may be valuable.

NurExone Biologic is focused on developing an exosome-based drug platform targeting damage in the central nervous system (CNS), with initial emphasis on treating spinal cord injuries. Their patent portfolio demonstrates two complementary core themes: (1) methods and compositions for efficiently loading extracellular vesicles (exosomes) with therapeutic cargos—including carbohydrates and active agents—and (2) the application of RNA interference (RNAi) oligonucleotides (e.g., siRNA, shRNA) against molecular targets like PTEN or components of perineuronal networks. In the context of CNS injuries, PTEN inhibition has been shown to promote axon regeneration, while modulation of perineuronal networks is thought to enhance neuroplasticity and recovery after trauma[Source][Source]. Exosomes represent a promising delivery vehicle for these RNA modalities thanks to their ability to cross biological barriers and selectively target neural tissues[Source].

Indications where NurExone’s exosome platform could be particularly valuable include:

• Spinal cord injury (SCI)
• Traumatic brain injury (TBI)
• Stroke (ischemic and hemorrhagic)
• Other severe CNS trauma with limited regenerative capacity (potentially including neurodegenerative diseases in the future)

The recent publication on Merkel cell carcinoma is likely not directly related to their CNS-focused technology, but rather reflects broader research collaborations[Source].

Potential acquirer profiles:

1. Larger biopharma companies with advanced neurology and CNS pipelines—especially those with programs in spinal cord injury, TBI, or regenerative neurology. Examples: Biogen, Roche/Genentech, Novartis, Eli Lilly, Johnson & Johnson.
2. Pharma and biotech companies with significant investments in RNA therapeutics or exosome delivery platforms. Examples: Ionis Pharmaceuticals, Alnylam, Moderna, Exopharm, Codiak BioSciences.
3. Device or regenerative medicine companies interested in combination therapies for CNS repair (e.g., Medtronic, Stryker for adjunct technologies).

Sample search query for company identification:

("spinal cord injury" OR "traumatic brain injury" OR "CNS trauma" OR "axon regeneration" OR "neuroregeneration" OR "stroke" OR "brain injury") AND (neurology OR CNS OR "central nervous system" OR neurorepair)

NurExone’s innovative exosome platform for CNS injury presents strategic value both as a standalone asset and as a synergistic addition to companies invested in advanced RNA delivery or neurological regeneration.

</aside>

</aside>

<aside> 4️⃣

All results: AI → Report: Collaboration Potential

Collaboration Context:

<aside> ❓

We are a biotech startup identifying potential acquirers mid- to long term

</aside>

Criteria:

<aside> ❓

Find below context on who our exosome technology may be valuable.

NurExone Biologic is focused on developing an exosome-based drug platform targeting damage in the central nervous system (CNS), with initial emphasis on treating spinal cord injuries. Their patent portfolio demonstrates two complementary core themes: (1) methods and compositions for efficiently loading extracellular vesicles (exosomes) with therapeutic cargos—including carbohydrates and active agents—and (2) the application of RNA interference (RNAi) oligonucleotides (e.g., siRNA, shRNA) against molecular targets like PTEN or components of perineuronal networks. In the context of CNS injuries, PTEN inhibition has been shown to promote axon regeneration, while modulation of perineuronal networks is thought to enhance neuroplasticity and recovery after trauma[Source][Source]. Exosomes represent a promising delivery vehicle for these RNA modalities thanks to their ability to cross biological barriers and selectively target neural tissues[Source].

Indications where NurExone’s exosome platform could be particularly valuable include:

• Spinal cord injury (SCI)
• Traumatic brain injury (TBI)
• Stroke (ischemic and hemorrhagic)
• Other severe CNS trauma with limited regenerative capacity (potentially including neurodegenerative diseases in the future)

The recent publication on Merkel cell carcinoma is likely not directly related to their CNS-focused technology, but rather reflects broader research collaborations[Source].

Potential acquirer profiles:

1. Larger biopharma companies with advanced neurology and CNS pipelines—especially those with programs in spinal cord injury, TBI, or regenerative neurology. Examples: Biogen, Roche/Genentech, Novartis, Eli Lilly, Johnson & Johnson.
2. Pharma and biotech companies with significant investments in RNA therapeutics or exosome delivery platforms. Examples: Ionis Pharmaceuticals, Alnylam, Moderna, Exopharm, Codiak BioSciences.
3. Device or regenerative medicine companies interested in combination therapies for CNS repair (e.g., Medtronic, Stryker for adjunct technologies).

Sample search query for company identification:

("spinal cord injury" OR "traumatic brain injury" OR "CNS trauma" OR "axon regeneration" OR "neuroregeneration" OR "stroke" OR "brain injury") AND (neurology OR CNS OR "central nervous system" OR neurorepair)

NurExone’s innovative exosome platform for CNS injury presents strategic value both as a standalone asset and as a synergistic addition to companies invested in advanced RNA delivery or neurological regeneration.

</aside>

Report Instructions:

<aside> ❓

• The goal of this report is to identify likely acquirers to help us navigate strategic decisions, inform investors, establish early contact with those players, and know how to get them interested.
• Structure the report into clearly numbered sections with descriptive headings.
• Begin with a concise introduction and a high-level background overview of the topic to set context.
• Where relevant, evaluate and score profiles using well-defined criteria on a 1–10 scale. Always include a clear scoring legend explaining what low vs high scores represent.
• Include at least one table that compares and ranks the evaluated profiles. Use one column per key criterion with a scoring on a 1-10 scale, include an overall ranking, and provide concise justification for each score.
• Segment the evaluated profiles into Tier 1, Tier 2, and Tier 3 players based on the scoring and/or qualitative assessment. For each tier, explain why profiles fall into that tier and clearly articulate the differences between Tier 1, Tier 2, and Tier 3.
• Provide a detailed, in-depth assessment of the best-fit (Tier 1) profiles, focusing on strategic relevance and practical implications.
• Identify and explain any notable trends, patterns, or clusters that emerge across the evaluated profiles.
• Summarize the key challenges, risks, and constraints, as well as the main opportunities.
• Translate the analysis into clear, actionable strategic recommendations.
• Add any additional sections that meaningfully increase insight or decision value.
• Conclude with a concise, half-page Executive Summary suitable for sharing directly with senior management. </aside>

</aside>

<aside> 5️⃣

Report:

• Read Report here: (click to open)
• Assess the detailed assessment per potential strategic partner in Excel here: (click to open) </aside>